Survival of pancreatic cancer cells lacking KRAS function

Survival of pancreatic cancer cells lacking KRAS function

Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on KRAS remains incompletely understood. H...

Full description

Bibliographic Details
Main Authors:	Noll, Elisa M., Sprick, Martin R., Trumpp, Andreas, Muzumdar, Mandar, Chen, Pan-Yu, Dorans, Kimberly, Chung, Katherine Minjee, Bhutkar, Arjun, Hong, Erin, Jacks, Tyler E.
Other Authors:	Massachusetts Institute of Technology. Department of Biology
Format:	Article
Published:	Nature Publishing Group 2017
Online Access:	http://hdl.handle.net/1721.1/112693 https://orcid.org/0000-0002-4450-7570 https://orcid.org/0000-0001-9119-8718 https://orcid.org/0000-0001-5785-8911

Similar Items

Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
by: Dorans, Kimberly, et al.
Published: (2017)

Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
by: Chen, Pan-Yu, et al.
Published: (2020)

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
by: Shao, Diane D., et al.
Published: (2016)

Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma
by: Chung, Katherine Minjee, et al.
Published: (2021)

Codon-specific KRAS mutations predict survival in advanced pancreatic cancer
by: A. Boilève, et al.
Published: (2024-03-01)

Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma
by: Marion Alhenc-Gelas, et al.
Published: (2019-01-01)

Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer
by: Tao, Zhimin, et al.
Published: (2021)

Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer
by: Tao, Zhimin, et al.
Published: (2022)

Investigating the requirement of KRAS for the maintenance of pancreatic cancer
by: Chen, Pan-Yu
Published: (2016)

Intercepting Pancreatic Cancer: Our Dream Teamʼs Resolve to Stop Pancreatic Cancer
by: Jacks, Tyler E
Published: (2020)

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01)

Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenocarcinoma
by: Won-Gun Yun, et al.
Published: (2025-01-01)

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
by: Jacob E. Till, et al.
Published: (2024-07-01)

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma
by: Politi, Katerina, et al.
Published: (2017)

Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
by: Szu-Aun Long, et al.
Published: (2024-05-01)

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
by: Anna Linehan, et al.
Published: (2024-03-01)

iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer
by: Lo, Justin H., et al.
Published: (2020)

Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks
by: Lukas Perkhofer, et al.
Published: (2019-01-01)

Down-Regulation of AKT Proteins Slows the Growth of Mutant-KRAS Pancreatic Tumors
by: Chuankai Chen, et al.
Published: (2024-06-01)

Metabolomic Approach to Identify Potential Biomarkers in KRAS-Mutant Pancreatic Cancer Cells
by: Boyun Kim, et al.
Published: (2024-04-01)

Targeting the Leukemic stem cell protein machinery by inhibition of mitochondrial pyrimidine synthesis
by: Elisa Donato, et al.
Published: (2022-06-01)

Pancreatic Function, Type 2 Diabetes, and Metabolism in Aging
by: Zhenwei Gong, et al.
Published: (2012-01-01)

Progressive Genomic Instability in the FVB/Kras[superscript LA2] Mouse Model of Lung Cancer
by: To, Minh D., et al.
Published: (2014)

The loss of ATRX increases susceptibility to pancreatic injury and oncogenic KRAS in female but not male mice
by: Young, C, et al.
Published: (2018)

Investigation of the efficacy of siRNA-mediated KRAS gene silencing in pancreatic cancer therapy
by: Büşra Küçükekmekci, et al.
Published: (2024-11-01)

Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis.
by: Shivan Sivakumar, et al.
Published: (2017-01-01)

Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma
by: Gaku Shimane, et al.
Published: (2024-09-01)

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
by: Dimitrios Stefanoudakis, et al.
Published: (2024-03-01)

Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
by: Juhi Mody, et al.
Published: (2024-03-01)

Corrigendum to “Pancreatic Function, Type 2 Diabetes, and Metabolism in Aging”
by: Zhenwei Gong, et al.
Published: (2017-01-01)

A pan-KRAS degrader for the treatment of KRAS-mutant cancers
by: Jie Yang, et al.
Published: (2024-06-01)

HIF-2α deletion promotes Kras-driven lung tumor development
by: Mazumdar, Jolly, et al.
Published: (2014)

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
by: Sayin, Volkan I., et al.
Published: (2018)

p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
by: Miller, P, et al.
Published: (2023)

In Silico Identification of Dysregulated miRNAs Targeting <i>KRAS</i> Gene in Pancreatic Cancer
by: Asbiel Felipe Garibaldi-Ríos, et al.
Published: (2024-07-01)

THZ1: Towards KRAS mutation‐based precision medicine against pancreatic ductal adenocarcinoma
by: Yansong Qin, et al.
Published: (2024-06-01)

Discipline in the secondary classroom : a problem-by-problem survival guide /
by: 423320 Sprick, Randall S.
Published: (1985)

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
by: Kohei Maruyama, et al.
Published: (2025-01-01)

Lack of Advertising, the Biggest Challenge to Media Survival in Algeria
by: Leila BOULKAIBET
Published: (2024-06-01)

Effect of KRAS mutation status on clinicopathological characteristics and overall survival in patients with rectal cancer
by: Shengbin Zheng, et al.
Published: (2025-01-01)